💡 Suggest / Edit
← Wiki Index / Microbiology & Immunology / Parthanatos
🦠 Microbiology & Immunology

Parthanatos

Parthanatos is a caspase-independent modality of regulated cell death driven by hyperactivation of poly(ADP-ribose) polymerase-1 (PARP-1), in which poly(ADP-ribose) polymers trigger mitochondrial release of Apoptosis-Inducing Factor (AIF) and nuclear translocation of the AIF–MIF nuclease complex to cleave genomic DNA.

9 min read • Updated October 2026 • Knowledge Wiki • AI-Assisted & Human-Supervised

Parthanatos (a portmanteau combining PAR [poly(ADP-ribose) polymer], the toxic signaling molecule synthesized by PARP-1, with Thanatos, the Greek personification of death) is a distinct, genetically regulated, caspase-independent modality of cell death in neurobiology, immunology, and pathology driven by the overactivation of the nuclear DNA-damage sensor enzyme poly(ADP-ribose) polymerase-1 (PARP-1, ARTD1). Discovered, mechanistically mapped, and named by Ted M. Dawson, Valina L. Dawson, Seong-Woon Yu, Hongmin Wang, and colleagues at Johns Hopkins University between 2002 and 2016, parthanatos accounts for the majority of acute neuronal and parenchymal cell loss in cerebral ischemia-reperfusion injury (stroke), glutamate NMDA-receptor excitotoxicity, Parkinson disease, Huntington disease, myocardial infarction, and reactive oxygen/nitrogen species (peroxynitrite, ONOO−) tissue injury. Unlike canonical apoptosis (which requires caspase-3/7/8/9 activation and cleaves DNA into 180 bp internucleosomal ladders via CAD), necroptosis (RIPK1/RIPK3/MLKL pores), or pyroptosis (gasdermin pores), parthanatos operates through a direct nuclear-to-mitochondrial-to-nuclear signaling loop: hyperactivated PARP-1 consumes cellular NAD+ to synthesize branched poly(ADP-ribose) (PAR) polymers that exit the nucleus and bind directly to mitochondrial Apoptosis-Inducing Factor (AIF), releasing a 57 kDa AIF fragment that recruits the cytosolic nuclease Macrophage Migration Inhibitory Factor (MIF) into the nucleus to shred genomic DNA into 20 to 50 kilobase fragments (Yu et al., 2002; Andrabi et al., 2006; Fatokun et al., 2014; Wang et al., 2016).

Physiological DNA Repair vs. Pathological PARP-1 Hyperactivation

Under normal homeostatic conditions, PARP-1 (an abundant 116 kDa nuclear enzyme containing three N-terminal zinc-finger DNA-binding domains, a central automodification BRCT domain, and a C-terminal catalytic ART domain) acts as the first responder to single-strand and double-strand DNA breaks:

  • When mild oxidative stress or base excision repair creates single-strand nicks in genomic DNA, PARP-1 binds the nick within seconds, increasing its catalytic activity 500-fold. Using nicotinamide adenine dinucleotide (NAD+) as its substrate, PARP-1 cleaves the nicotinamide-ribosyl bond and polymerizes linear and branched chains of negatively charged ADP-ribose units (PAR polymers, up to 200 units long) onto itself, histones H1/H2B, and repair proteins, recruiting the scaffold protein XRCC1, DNA polymerase β, and DNA ligase III to seal the break, after which poly(ADP-ribose) glycohydrolase (PARG) rapidly degrades the PAR chains back to free ADP-ribose.
  • The Pathological Threshold (Excitotoxicity and Nitrosative Stress): During cerebral ischemia, traumatic brain injury, or pathological overstimulation of NMDA-type glutamate receptors, massive Ca2+ influx through NMDA channels activates neuronal nitric oxide synthase (nNOS / NOS1) to produce nitric oxide (NO•), which reacts at diffusion-controlled rates with mitochondrial superoxide (O2•−) to form peroxynitrite (ONOO−). Peroxynitrite and hydroxyl radicals inflict thousands of simultaneous DNA strand breaks across the genome, driving runaway PARP-1 hyperactivation that outstrips PARG degradation and floods the cell with free and protein-bound high-molecular-weight PAR polymers (Dawson & Dawson, 2017).

The Six-Step Molecular Cascade of Parthanatos

Between 2002 and 2016, the Dawson laboratory established that parthanatos is not merely passive energy starvation from NAD+/ATP depletion (as originally proposed in Nathan Berger's 1985 "suicide hypothesis"), but an active, PAR-polymer-mediated signaling pathway consisting of six sequential steps (Yu et al., 2002, 2006; Andrabi et al., 2006, 2011; Wang et al., 2011, 2016):

Cascade StepKey Molecular EffectorsSubcellular CompartmentBiochemical Mechanism & Experimental Proof
1. Pathological PARP-1 Hyperactivation & PAR Polymer AccumulationPARP-1 (activated by ONOO−, alkylating agent MNNG, or ROS DNA breaks) vs. PARG (degradative enzyme)NucleusPARP-1 synthesizes long, branched >60-mer poly(ADP-ribose) (PAR) polymers; genetic deletion of Parp1 or pharmacological PARP inhibitors (olaparib, talazoparib, PJ34, DPQ) completely prevents cell death, whereas Parg knockdown accelerates parthanatos (Andrabi et al., 2006).
2. PAR Polymer Inhibition of Hexokinase-1 & Glycolytic Bioenergetic CollapseFree PAR polymers binding the PAR-binding motif (PBM) of mitochondrial-outer-membrane-associated Hexokinase-1 (HK1)Nucleus → Cytosol / Outer Mitochondrial MembraneBefore NAD+ is fully depleted, exported PAR polymers bind directly to Hexokinase-1 (the rate-limiting first enzyme of glycolysis), dissociating HK1 from VDAC on the mitochondria and halting glycolytic flux—explaining why replenishing pyruvate/NAD+ rescues the metabolic block only if AIF translocation is also prevented (Andrabi et al., 2014).
3. Direct Binding of PAR to Mitochondrial Apoptosis-Inducing Factor (AIF)High-molecular-weight PAR binding the high-affinity basic PAR-binding site (Arg588, Lys589, Lys592) on the 62 kDa mature mitochondrial flavoprotein AIF (AIFM1)Outer / Intermembrane Mitochondrial SurfaceA distinct pool of ~20–30% of mature AIF resides anchored on the cytosolic side of the outer mitochondrial membrane (OMM). Binding of negatively charged PAR polymers induces a conformational change that releases a 57 kDa soluble truncated AIF from the OMM without requiring calpain-1 or cathepsin cleavage (Yu et al., 2006; Wang et al., 2009, 2011).
4. Cytosolic Recruitment of MIF (The Parthanatos-Associated AIF Nuclease, PAAN)Released AIF (57 kDa) + cytosolic Macrophage Migration Inhibitory Factor (MIF)CytosolBecause AIF itself lacks intrinsic endonuclease activity, its identity as a DNA-cleaving factor was a 17-year mystery until Yingfei Wang, Ted Dawson et al. (2016, Science) screened >160 candidate proteins and discovered that MIF possesses a 3′-exonuclease and structural 3-PD endonuclease catalytic site (Glu22). Cytosolic AIF binds MIF with high affinity and ferries it into the nucleus; mutating MIF's nuclease site (E22Q) without altering its cytokine activity completely blocks parthanatos and reduces stroke infarct volume by >70%.
5. Nuclear Translocation & 20–50 kb Large-Scale Chromatin FragmentationAIF–MIF (PAAN) heterocomplex + histone H2AX / cyclophilin ANucleusThe AIF–MIF complex binds single-stranded DNA at stem-loop structures and cleaves genomic chromatin into large 20 to 50 kb fragments accompanied by peripheral chromatin condensation—with zero caspase-3/7 activation and zero rescue by pan-caspase inhibitor Z-VAD-FMK (Wang et al., 2016).
6. Phosphatidylserine Exposure & Plasma Membrane PermeabilizationLoss of ATP-dependent flippase activity and secondary membrane rupturePlasma MembraneDying cells expose outer-leaflet phosphatidylserine and lose membrane integrity within 6 to 12 hours, releasing inflammatory DAMPs.

Pathophysiological Role in Stroke, Parkinson Disease, and Therapeutic Inhibition

Because post-mitotic neurons and cardiomyocytes are acutely vulnerable to nitrosative DNA damage and PARP-1 hyperactivation, parthanatos is a primary driver of human neurodegenerative and ischemic disease (Fatokun et al., 2014; Dawson & Dawson, 2017):

  • Ischemic Stroke and Myocardial Infarction: In middle cerebral artery occlusion (MCAO) mouse models of ischemic stroke, Eliakim, Snyder, and Dawson (1997) demonstrated that Parp1−/− knockout mice (or wild-type mice treated with PARP-1 inhibitors or carrying the PAR-binding-deficient Aifm1R588A/K589A/K592A knock-in mutation or nuclease-dead MifE22Q mutation) exhibit an up to 70% to 80% reduction in cerebral infarct volume and preserved motor function (Eliasson et al., 1997; Wang et al., 2011, 2016).
  • Parkinson Disease and Pathologic α-Synuclein Propagation (Kam et al., 2018, Science): In 2018, Tae-In Kam, Valina Dawson, Ted Dawson, and colleagues discovered a self-amplifying feed-forward loop between α-synuclein (SNCA) pathology and parthanatos in Parkinson disease: preformed α-synuclein fibrils (PFFs) activate nitric oxide synthase and DNA damage in dopaminergic substantia nigra neurons, activating PARP-1; the resulting PAR polymers bind directly to α-synuclein monomers, accelerating their fibrillization by >25-fold and converting them into a hyper-toxic, compact PAR-modified α-synuclein strain that kills neighboring neurons via parthanatos. Administering FDA-approved clinical PARP inhibitors (veliparib, rucaparib, talazoparib) or deleting Parp1 completely prevented dopaminergic neuron loss and motor deficits in mouse models of Parkinson disease, while elevated cerebrospinal fluid PAR levels were confirmed in human Parkinson patients (Kam et al., 2018; Park et al., 2022).
  • Selective PAAN/MIF Nuclease Inhibitors (PAANIB-1): Because long-term systemic inhibition of PARP-1 blocks physiological DNA repair in dividing bone-marrow and gut cells, Park et al. (2022, Cell) developed a brain-penetrant small-molecule inhibitor (PAANIB-1) that selectively blocks the MIF (PAAN) endonuclease catalytic pocket without affecting PARP-1 DNA repair or MIF's immunological cytokine function—preventing neurodegeneration across three independent mouse models of Parkinson disease.

References

  1. Eliasson, M. J. L., Sampei, K., Mandir, A. S., Hurn, P. D., Traystman, R. J., Bao, J., Pieper, A., Wang, Z.-Q., Dawson, T. M., Snyder, S. H., & Dawson, V. L. (1997). Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nature Medicine, 3(10), 1089–1095. https://doi.org/10.1038/nm1097-1089
  2. Yu, S.-W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., & Dawson, V. L. (2002). Mediation of poly(ADP-ribose) polymerase-1–dependent cell death by apoptosis-inducing factor. Science, 297(5579), 259–263. https://doi.org/10.1126/science.1072221
  3. Andrabi, S. A., Kim, N. S., Yu, S.-W., Wang, H., Koh, D. W., Sasaki, M., Klaus, J. A., Otsuka, T., Zhang, Z., Koehler, R. C., Hurn, P. D., Poirier, G. G., Dawson, V. L., & Dawson, T. M. (2006). Poly(ADP-ribose) (PAR) polymer is a death signal. Proceedings of the National Academy of Sciences, 103(48), 18308–18313. https://doi.org/10.1073/pnas.0606526103
  4. Wang, Y., Kim, N. S., Haince, J.-F., Kang, H. C., David, K. K., Andrabi, S. A., Poirier, G. G., Dawson, V. L., & Dawson, T. M. (2011). Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1–dependent cell death (parthanatos). Science Signaling, 4(167), ra20. https://doi.org/10.1126/scisignal.2000902
  5. Wang, Y., An, R., Umanah, G. K., Park, H., Nambiar, K., Eacker, S. M., Kim, B., Bao, L., Harraz, M. M., Chang, C., Chen, R., Wang, J. E., Kam, T.-I., Jeong, J. S., Xie, Z., Neff, S., Bowlby, R., Linton, J., Poirier, G. G., … Dawson, T. M. (2016). A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science, 354(6308), aad6872. https://doi.org/10.1126/science.aad6872
  6. Kam, T.-I., Mao, X., Park, H., Chou, S.-C., Karuppagounder, S. S., Umanah, G. K., Yun, S. P., Brahmachari, S., Panicker, N., Chen, R., Andrabi, S. A., Qi, C., Fabre, G. E., Poirier, G. G., Troncoso, J. C., Dawson, V. L., & Dawson, T. M. (2018). Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease. Science, 362(6414), eaat8407. https://doi.org/10.1126/science.aat8407
  7. Park, H., Kam, T.-I., Peng, H., Chou, S.-C., Mehrabani-Tabari, A. A., Song, J.-J., Yin, X., Karuppagounder, S. S., Umanah, G. K., Rao, A. V. S., Choi, Y., Aggarwal, A., Chang, S., Kim, H., Byun, J., Liu, J. O., Dawson, T. M., & Dawson, V. L. (2022). PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson's disease. Cell, 185(11), 1943–1959.e21. https://doi.org/10.1016/j.cell.2022.04.020
🧬 Support Open Science
Explore interactive science games on LowKey Games or browse scientific apparel & accessories in the CRV Science Shop.
💡 Spot an inaccuracy or have primary literature to expand this article?
Submit a citation or revision note using your shared CRV Science / LowKey Games profile ID.
Suggest Revision